<DOC>
	<DOCNO>NCT00633165</DOCNO>
	<brief_summary>This Phase II , multicenter , open-label clinical trial design determine efficacy safety Brostallicin administer every 3 week patient myxoid liposarcoma ( 12 ; 16 ) translocation . The primary objective study determine response rate follow Brostallicin administration .</brief_summary>
	<brief_title>Brostallicin Clinical Trial Myxoid Liposarcoma</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Liposarcoma , Myxoid</mesh_term>
	<criteria>1 . Patient provide informed consent . 2 . Histologically confirm myxoid liposarcoma . 3 . Patients metastatic and/or unresectable myxoid liposarcoma progressive standard curative measure exist longer effective . 4 . Patient measurable tumor CT , spiral CT , MRI scan meet RECIST criterion . 5 . Age ≥18 year 6 . Karnofsky performance status ( KPS ) ≥ 70 % ( see Appendix III ) . 7 . Life expectancy least 3 month . 8 . Acceptable liver function : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ( SGOT ) , ALT ( SGPT ) alkaline phosphatase ≤ 2.5 time ULN ( liver metastasis present , ≤ 5 × ULN allow ) . 9 . Acceptable renal function : For patient serum creatinine within normal limit , OR calculate creatinine clearance ≥ 60 mL/min/1.73 ( 2 ) patient creatinine level institutional normal . 10 . Acceptable hematologic status : Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm ( 3 ) ( 1.5 ×10 ( 9 ) /L ) Platelet count ≥ 100,000 platelet/mm ( 3 ) ( 100 ×10 ( 9 ) /L ) Hemoglobin ≥ 9 g/dL . 1 . Patient receive follow within specified time period prior initiation treatment study : Chemotherapy , major surgery , significant traumatic injury , irradiation , whether conventional investigational within 28 day MitomycinC nitrosurea within 42 day . ET743 time ( Stage 1 ) . 2 . Patients heavily pretreated chemotherapy radiation , define follow : ≥ 12 cycle alkylating agentcontaining regimen , &gt; 2 cycle carboplatin , &gt; 2 cycle mitomycin C , irradiation 25 % bone marrowcontaining area , highdose chemotherapy require hematopoietic stemcell reinfusion . 3 . Known hypersensitivity study drug component . 4 . Uncontrolled brain metastasis judgement Investigator . 5 . Abnormal cardiac cardiovascular function , serious cardiac illness medical condition previous 6 month include , confine : New York Heart Association ( NYHA ) grade 2 high congestive heart failure ( CHF ) angioplasty placement coronary stent within previous 6 month Myocardial infarction within past 6 month Highrisk uncontrolled arrhythmias Angina pectoris require antianginal medication Has clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension ( e.g. , blood pressure : systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ) . 6 . Pregnant lactating female . All patient ( male female ) fertile must agree use effective barrier method birth control ( i.e. , latex condom , diaphragm , cervical cap , etc ) avoid pregnancy . 7 . Not recover acute toxicity previous therapy prior enrollment . 8 . History prior malignancy within 3 year , except basal cell squamous cell carcinoma skin , carcinoma situ cervix breast . 9 . Any evidence serious and/or unstable preexist medical , psychiatric , condition ( include laboratory abnormality ) could interfere patient safety obtain informed consent . 10 . Any active uncontrolled infection include AIDS , hepatitis B C. 11 . Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol follow schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>myxoid liposarcoma</keyword>
</DOC>